Mikroforum Ring 2
55234 Wendelsheim, de
+49 (6734) 9622-0
AESKU.GROUP - Certainty thanks to comprehensive testing possibilities
AESKU.GROUP, a leading biotechnology company, based in Wendelsheim, Germany, offers - with its portfolio of more than 1100 products - the possibility to support patients, doctors, and laboratories in the diagnosis of SARS-CoV-2 late consequences
However, the research situation and the associated information of the population is rather diffuse. Press releases outdo each other with the issuing of hastily published research results, and the uncertainty of patients is growing. On the one hand, reports state that patients who have recovered from an infection are protected against reinfection. On the other hand, the protection is said to be based on the strength of the previous infection, and following that, a third party promptly reports reinfections. In this jumble of reports, investigations of the late consequences of SARS-CoV-2 infections are almost lost.
Such late effects can vary from patient to patient, and many factors play a role. According to a recent study (Carfi A. et al. 2020) of 143 patients treated in Italian hospitals, 87 percent of them still suffered from at least one symptom 60 days after the disease's onset. A high proportion of people still reported fatigue (53.1%), shortness of breath (43.4%), joint pain (27.3%), and chest pain (21.7%). On average, only slightly more than one in ten patients reported being free of any symptoms.
While the frequently cited symptoms mainly sound like the late effects of pneumonia, which in most cases is the most severe of the COVID-19 diseases, an infection with the SARS-CoV-2 virus can also damage the heart muscle, intestine, kidneys, vascular lining, and the nervous system.
In individual cases, Guillain-Barré syndrome also occurs as an inflammatory disease of the nerves. The Syndrome can lead to paralysis of the legs, arms, trunk, and respiratory muscles. According to the German Society of Neurology, these problems occur not only in patients who belong to the risk group but also in those who were perfectly healthy before their infection. The research group around Harriet Kemp from Imperial College London (Kemp H. et al. 2020) also reports patients who complain of partially diffuse chronic pain after a completed SARS-CoV-2 infection.
The AESKU® product portfolio offers a wide range of possibilities to investigate and monitor such late effects and exclude a possible autoimmune disease freshly established after a severe SARS-CoV-2 infection.
For example immunoblot tests of the AESKUBLOTS® range on Vasculitis, Myositis, Gastroenterology and Rheumatology, or ELISA-tests from the AESKULISA® product lines Hemostasis, Gastroenterology, Vasculitis, Thrombosis and Rheumatology
But furthermore, the current threat of SARS-CoV-2 must not be lost out of sight. For the exclusion of an acute or recent infection, our quantitative AESKULISAs SARS-CoV-2 IgA, IgM, and IgG are recommended.
Among others, our AESKUBLOTS®
4001 ANA-17 Pro
4002 Vasculitis Pro
4003 Myositis Pro
4005 Gastro Pro
4008 ANA-17 Comp
and our AESKULISA®:
3901 Protein C
3902 Protein S
3500 Gliadin Check
3509 Crohn‘s Check
3510 CeliCheck New Generation
3515 DGP Check
3302 PR3 sensitive
3291 Hit II-Check
3324 Phospholipid-Screen GM
shall be mentioned here.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.